“…Dos Santos et al concluded that tocilizumab, abatacept, etanercept, and golimumab had a significantly higher persistence, and infliximab showed a significantly lower persistence compared with According to real-world data, the persistence of biological agents in RA can be affected by various factors beyond efficacy and safety, including previous biological treatments, comedications, and baseline disease activity [21]. Thus, although biological treatments with different mechanisms of action have demonstrated similar efficacy in clinical trials, differences in persistence have been reported among different classes of bDMARDs in our data and previous studies [8,[17][18][19], although conflicting data also exist [22,23]. The exact reasons for this finding remain unclear; however, the pharmacological characteristics of tocilizumab can be considered a potential cause.…”